JOHN DORSEY: Open Payments
NPI 1114392800 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,759 in 202 payments from 25 companies in 2025. Trend: 2023 $4,208 · 2024 $4,772 · 2025 $4,759
Food & beverage: $4,759
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $851 |
| Madrigal Pharmaceuticals | 14 | $719 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $484 |
| Janssen Biotech, Inc. | 12 | $258 |
| GENZYME CORPORATION | 8 | $247 |
| Lilly USA, LLC | 12 | $238 |
| Janssen Scientific Affairs, LLC | 2 | $212 |
| QOL Medical, LLC | 9 | $207 |
| Ardelyx, Inc. | 10 | $203 |
| Gilead Sciences, Inc. | 9 | $185 |
Products named: REZDIFFRA, RINVOQ, TREMFYA, ENTYVIO, DUPIXENT, SKYRIZI, OMVOH, Sucraid.
Industry payments across AZ — which companies pay providers there.
